Complement C3 activation is required for antiphospholipid antibody-induced fetal loss

Journal of Experimental Medicine

Volumn 195, Issue 2, 2002, Pages 211-220

  Michael Holers, V ^a   Girardi, Guillermina ^b   Mo, Lian ^b   Guthridge, Joel M ^a   Molina, Hector ^c   Pierangeli, Silvia S ^d   Espinola, Ricardo ^d   Xiaowei, Liu E ^d   Mao, Dailing ^c   Vialpando, Christopher G ^a   Salmon, Jane E ^b,e  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOREHOUSE SCHOOL OF MEDICINE   (United States)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Anticardiolipin antibodies; Complement; Lupus; Pregnancy; Thrombosis

Indexed keywords

COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; LIGANDIN; PHOSPHOLIPID ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL ACTIVATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FETUS WASTAGE; GROWTH RETARDATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; TISSUE INJURY;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT C3; EPITOPES; FEMALE; FETAL DEATH; HUMANS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PREGNANCY;

EID: 0037148520     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.200116116     Document Type: Article

References (42)

1. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: A model for autoimmune fetal loss
2. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice
3. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal antibodies
4. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice
5. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered B2-glycoprotein 1
6. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies
7. Placental pathology in systemic lupus erythematosus: A prospective study
8. Activation of cultured vascular endothelium by antiphospholipid antibodies
9. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro
10. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
11. Mouse complement regulatory protein Crry/p65 utilizes the specific mechanisms of both decay-accelerating factor and membrane cofactor protein
12. A critical role for the murine complement regulator Crry in fetomaternal tolerance
13. Complement and pregnancy: New insights into the immunobiology of the fetomaternal relationship
14. Immunology of reproduction: Protecting the placenta
15. Immunofluorescent studies of the uteroplacental arteries in normal pregnancy
16. Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy
17. Preferential expression of complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy
18. Complement regulatory proteins at the fetomaternal interface during human placental development distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating (CD55)
19. Decayaccelerating factor protects human trophoblast from complement-mediated attack
20. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins
21. Structure, function and cellular expression of complement anaphylatoxin receptors
22. Membrane attack by complement: Assembly and biology, of terminal complement complexes
23. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity
24. Evaluation of the antiphospholipid antibody test: Report of an international workshop
25. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor
26. Intercellular adhesion molecule 1 expression is required for antiphospholipid antibodyinduced pregnancy loss
27. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA
28. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with antiphospholipid syndrome
29. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice
30. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells
31. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface
32. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
33. Affinity purified human antiphospholipid antibodies bind normal term placenta
34. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-β 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprorein I and induce endothelial activation
35. Antiphospholipid antibodies and the protein C pathway
36. The effects of complement activation on platelets
37. Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of antiphospholipid antibodies: β2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein
38. Hypocomplementemia with low C1s-C1r inhibitor complex in systemic lupus erythematosus
39. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy
40. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia
41. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis
42. Obstetric implications of antiphospholipid antibodies: Pregnancy loss and other complications